Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.49 |
| ▸ | SUV39H2 | Q9H5I1 | 4/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 2/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6156003 | 1.00 | DRD2 (0.49) | DRD2SUV39H2ARIMPDH2ALDH1A1 | |
| SCHEMBL6154416 | 0.87 | SUV39H2 (0.47) | DRD2SUV39H2IMPDH2ALDH1A1KDM4E | |
| SCHEMBL6154412 | 0.87 | SUV39H2 (0.47) | DRD2SUV39H2IMPDH2ALDH1A1KDM4E | |
| SCHEMBL6154460 | 0.87 | SUV39H2 (0.47) | DRD2SUV39H2IMPDH2ALDH1A1KDM4E | |
| SCHEMBL2390121 | 0.85 | DRD2 (0.44) | DRD2SUV39H2ALDH1A1GAADRD3 | |
| SCHEMBL2390116 | 0.85 | DRD2 (0.44) | DRD2SUV39H2ALDH1A1GAADRD3 | |
| SCHEMBL31008890 | 0.79 | DRD2 (0.45) | DRD2SUV39H2ALDH1A1GAADRD3 | |
| SCHEMBL31206037 | 0.79 | DRD2 (0.45) | DRD2SUV39H2ALDH1A1GAADRD3 | |
| SCHEMBL6154808 | 0.79 | SUV39H2 (0.46) | DRD2SUV39H2ARALDH1A1KDM4E | |
| SCHEMBL31184825 | 0.77 | ALDH1A1 (0.52) | DRD2SUV39H2ALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | DRD2 3058/4885SUV39H2 533/4885AR 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.